In the Claims:

1. **(original)** Compounds of formula:



(I)

in which:

- R_1 represents hydrogen or a $(C_1\text{-}C_4)$alkyl;
- R_2 represents: . a $(C_3\text{-}C_7)$alkyl group,
  - an indan-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, said groups being unsubstituted or substituted by a halogen atom and/or a methyl group;
  - a saturated, single-nitrogen heterocyclic radical of 5 to 7 atoms, the nitrogen atom being substituted by a $(C_1\text{-}C_4)$alkyl, benzyl, $(C_1\text{-}C_3)$alkoxycarbonyl or $(C_1\text{-}C_4)$alkanoyl group;
  - a group NR_9R_{10};
  - a group $(CH_2)_nR_{11}$, $CH(CH_3)R_{11}$, $(CH_2)_mN(CH_3)R_{11}$;
  - a $C_3\text{-}C_{12}$ nonaromatic carbocyclic radical, unsubstituted or substituted one or more times by a methyl group;
- or R_1 and R_2 together with the nitrogen atom to which they are attached form either a piperazin-1-yl radical substituted in position 4 by a phenyl or benzyl group, or a piperidin-1-yl radical disubstituted in position 4 by a phenyl or benzyl group and by a $(C_1\text{-}C_4)$alkyl or $(C_1\text{-}C_3)$alkanoyl group; the phenyl or benzyl group substituents on the piperazin-1-yl radical or the piperidin-1-yl radical being unsubstituted or substituted by a halogen atom and/or a methyl group;
- R_3, R_4, R_5, R_6, R_7 and R_8 represent each independently of one another a hydrogen or halogen atom or a $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy or trifluoromethyl group;
- R_9 and R_{10} together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms containing or not containing a second heteroatom selected from O and N, said radical being

unsubstituted or substituted one or more times by a (C_1-C_4)alkyl, hydroxyl or (C_1-C_4)alkoxy group;

- R_{11} represents: . a phenyl which is unsubstituted or substituted by one or more substituents selected from a halogen atom and a methyl group;

- a heteroaryl radical of 6 to 10 atoms containing one or more nitrogen atoms;

- n represents 1, 2 or 3;
- m represents 0, 2 or 3;

and their salts, their solvates and their hydrates.

2. **(original)** A compound according to claim 1 of formula (I) in which:

- R_1 represents a hydrogen atom or a (C_1-C_4)alkyl group;
- R_2 represents a group NR_9R_{10} or a nonaromatic C_3-C_{12} carbocyclic radical which is unsubstituted or substituted one or more times by a methyl group;
- R_3, R_4, R_5, R_6, R_7 and R_8 represent each independently of one another a hydrogen or halogen atom or a (C_1-C_6)alkyl, (C_1-C_6)alkoxy or trifluoromethyl group;
- R_9 and R_{10} together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms, containing or not containing a second heteroatom selected from O and N, said radical being unsubstituted or substituted one or more times by a (C_1-C_4)alkyl group;

and their salts, their solvates and their hydrates.

3. **(currently amended)** ~~Compounds~~ A compound according to claim 1 ~~or claim 2~~ of formula (I) in which:

- R_1 represents a hydrogen atom; and/or
- R_2 represents a group selected from piperidin-1-yl, pyrrolidin-1-yl, cyclohexyl, spiro[5.5]undecanyl and 1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl; and/or
- at least one of the substituents R_3, R_4 and R_5 represents a halogen atom or a trifluoromethyl group; and/or
- at least one of the substituents R_6, R_7 and R_8 represents a halogen atom.

4. **(currently amended)** A process for preparing a compound of formula (I) according to claim 1 wherein ~~any one of claims 1 to 3, characterized in that~~ a functional derivative of terphenylic acid of formula:



(II)

in which R_3, R_4, R_5, R_6, R_7 and R_8 are as defined for a compound of formula (I) in claim 1 is treated with an amine of formula HNR_1R_2 (III) in which R_1 and R_2 are as defined for a compound of formula (I) in claim 1.

5. **(original)** Compounds of formula:



(IIa)

in which R_3, R_4, R_5, R_6, R_7 and R_8 are as defined for a compound of formula (I) in claim 1 and R represents a hydrogen atom or a (C_1-C_4)alkyl group, on condition that R_3, R_4, R_5, R_6, R_7 and R_8 are not simultaneously hydrogen, and on condition that, when R_4, R_5, R_7 and R_8 represent hydrogen, R_3 and R_6 do not simultaneously represent a fluorine atom in meta position, or a methoxy group in meta or para position, and on condition that when R_5 and R_8 represent hydrogen R_3, R_4 and R_5, R_6 do not simultaneously represent 3,4-dimethoxy groups.

6. **(original)** A compound according to claim 5 of formula (IIa) in which:

- R_3 is in position 4 and represents a halogen atom or a trifluoromethyl group;
- R_6 is in position 2 and represents a hydrogen or halogen atom;
- R_7 is in position 4 and represents a halogen atom;
- R_4, R_5 and R_8 are hydrogen.

7. **(cancelled)**

8. **(currently amended)** A pharmaceutical composition ~~characterized in that it~~ which comprises a compound of formula (I) according to claim 1 ~~any one of claims 1 to 3,~~ or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

9. **(currently amended)** ~~The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended~~ A method for treating any disease involving the CB_1 cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

10. **(currently amended)** ~~The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended~~ A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

11. **(new)** A compound according to claim 2 of formula (I) in which:

- R_1 represents a hydrogen atom or a $(C_1\text{-}C_4)$alkyl group;
- R_2 represents a group NR_9R_{10} or a nonaromatic $C_3\text{-}C_{12}$ carbocyclic radical which is unsubstituted or substituted one or more times by a methyl group;
- R_3, R_4, R_5, R_6, R_7 and R_8 represent each independently of one another a hydrogen or halogen atom or a $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy or trifluoromethyl group;
- R_9 and R_{10} together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms, containing or not containing a second heteroatom selected from O and N, said radical being unsubstituted or substituted one or more times by a $(C_1\text{-}C_4)$alkyl group;

and their salts, their solvates and their hydrates.

12. **(new)** A pharmaceutical composition which comprises a compound of formula (I) according to claim 2 or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

13. **(new)** A pharmaceutical composition which comprises a compound of formula (I) according to claim 3 or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

14. **(new)** A pharmaceutical composition which comprises a compound of formula (I) according to claim 11 or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

15. **(new)** A method for treating any disease involving the CB_1 cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.

16. **(new)** A method for treating any disease involving the CB_1 cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.

17. **(new)** A method for treating any disease involving the CB_1 cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 11.

18. **(new)** A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.

19. **(new)** A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.

20. **(new)** A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 11.